Biotechnology Assets (XMAD:BST) Valuation Rank


XMAD:BST Biotechnology Assets SA XMAD:BST
19 GF Score
Price €0.23
GF Value €0.30
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Biotechnology Assets Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Biotechnology Assets Valuation Rank Related Terms

XMAD:BST
19GF Score
Biotechnology Assets SA XMAD:BST
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?

Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued. The current stock price of €0.23 is trading 24.7% below its estimated GF Value™ of €0.30. GuruFocus considers Biotechnology Assets to be Modestly Undervalued.

Key valuation signals for XMAD:BST:

  • Valuation Rank:
  • GF Value™: €0.30 vs. price of €0.23 (24.7% below fair value)
  • GF Score™: 19/100 with 3 warning signs

No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biotechnology Assets Business Description

Address Avenida del Desarrollo Tecnologico, No. 11, Scientific and Technological Park, Jerez de la Frontera, ESP, 11591
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
19GF Score

Get the complete analysis for XMAD:BST

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.23
Price
€0.30
GF Value